Get the latest news, insights, and market updates on CGEN (Compugen Ltd.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Prothena (PRTA) delivered earnings and revenue surprises of +1.12% and -99.30%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock? Feb 19, 2026 - $CGEN
Compugen to Participate in Upcoming Investor Conferences
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that management will participate in the following upcoming investor conferences: Feb 19, 2026 - $CGEN
Compugen to Release Fourth Quarter and Full Year 2025 Results on Monday, March 2, 2026
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced that the Company will release its fourth quarter and full year 2025 financial results on Monday, March 2, 2026, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET. Feb 17, 2026 - $CGEN
Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today announced the appointment of Michele Holcomb, Ph.D., as a new independent director, effective February 11, 2026. Feb 12, 2026 - $CGEN
Compugen Monetizes Portion of Rilvegostomig Future Royalties to AstraZeneca for Up to $90 Million
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today announced that it has agreed with AstraZeneca to monetize a portion of Compugen's rilvegostomig future royalties. Compugen has amended the exclusive license agreement with AstraZeneca, previously entered into in March 2018, to strengthen Compugen's balance sheet and advance its innovative and differentiated immuno-oncology pipe Dec 17, 2025 - $CGEN
Compugen Reports Third Quarter 2025 Results
Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational target discovery powered by AI/ML, today reported financial results for the third quarter of 2025 and provided a corporate update. Nov 10, 2025 - $CGEN
Compugen: Q3 Earnings Snapshot
HOLON, Israel (AP) — Compugen Ltd. (CGEN) on Monday reported a loss of $7 million in its third quarter. On a per-share basis, the Holon, Israel-based company said it had a loss of 7 cents. The results surpassed Wall Street expectations. Nov 10, 2025 - $CGEN
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates
Compugen (CGEN) delivered earnings and revenue surprises of +22.22% and -14.43%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock? Nov 10, 2025 - $CGEN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple